{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:38:11Z","timestamp":1781887091694,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.radonc.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T06:54:51Z","timestamp":1663138491000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET\/CT in locally advanced cervical cancer"],"prefix":"10.1016","volume":"176","author":[{"given":"Kjersti","family":"Skipar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tord","family":"Hompland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti Vassmo","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayca","family":"L\u00f8ndalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Malinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar B.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esten S.","family":"Nakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"Bruheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Lyng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.09.002_b0005","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2017.01.033","article-title":"Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: a systematic review and meta-analysis","volume":"145","author":"Datta","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA3","article-title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)","volume":"39","author":"Mileshkin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","article-title":"Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial","volume":"36","author":"Gupta","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.radonc.2018.05.002","article-title":"Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer","volume":"127","author":"Fokdal","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.radonc.2018.05.016","article-title":"Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study","volume":"127","author":"Jensen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0040","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s00261-015-0363-6","article-title":"PET\/CT and MRI in the imaging assessment of cervical cancer","volume":"40","author":"Kusmirek","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40336-017-0238-7","article-title":"Hypoxia in cervical cancer: from biology to imaging","volume":"5","author":"Lyng","year":"2017","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.radonc.2020.01.026","article-title":"Quantitative imaging for radiotherapy purposes","volume":"146","author":"Gurney-Champion","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/RCT.0b013e31819e93af","article-title":"Diffusion-weighted magnetic resonance imaging of uterine cervical cancer","volume":"33","author":"Liu","year":"2009","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.radonc.2022.09.002_b0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/bjc.2017.121","article-title":"The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K(trans) in cervical cancer is explained by plasma flow rather than vessel permeability","volume":"116","author":"Dickie","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2022.09.002_b0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1102\/1470-7330.2008.0022","article-title":"The prognostic value of PET and PET\/CT in cervical cancer","volume":"8","author":"Grigsby","year":"2008","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2012.11.007","article-title":"Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome","volume":"107","author":"Andersen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2009.04.069","article-title":"A combined pharmacokinetic and radiologic assessment of dynamic contrast-enhanced magnetic resonance imaging predicts response to chemoradiation in locally advanced cervical cancer","volume":"75","author":"Semple","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.09.002_b0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13014-020-01526-2","article-title":"DCE-MRI of locally-advanced carcinoma of the uterine cervix: tofts analysis versus non-model-based analyses","volume":"15","author":"Lund","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0085","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.ejrad.2016.10.011","article-title":"Can diffusion-weighted magnetic resonance imaging predict survival in patients with cervical cancer? A meta-analysis","volume":"85","author":"Wang","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.radonc.2022.09.002_b0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12885-016-2619-0","article-title":"Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation","volume":"16","author":"Marconi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2022.09.002_b0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1148\/radiol.2015150400","article-title":"Association of apparent diffusion coefficient with disease recurrence in patients with locally advanced cervical cancer treated with radical chemotherapy and radiation therapy","volume":"279","author":"Gladwish","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2022.09.002_b0100","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cncr.22974","article-title":"The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival","volume":"110","author":"Kidd","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.09.002_b0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/RLU.0000000000001049","article-title":"Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer: a meta-analysis","volume":"41","author":"Sarker","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.radonc.2022.09.002_b0110","doi-asserted-by":"crossref","first-page":"519440","DOI":"10.3389\/fonc.2020.519440","article-title":"Diagnostic value of FDG PET\/MRI in females with pelvic malignancy-A systematic review of the literature","volume":"10","author":"Nguyen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-018-0403-7","article-title":"Spatial relationship of 2-deoxy-2-[(18)F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer","volume":"8","author":"Floberg","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmri.27311","article-title":"PET\/MRI in cervical cancer: associations between imaging biomarkers and tumor stage, disease progression, and overall survival","volume":"53","author":"Shih","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0125","doi-asserted-by":"crossref","first-page":"e0155333","DOI":"10.1371\/journal.pone.0155333","article-title":"Multiparametric [18F]Fluorodeoxyglucose\/[18F]Fluoromisonidazole positron emission tomography\/magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: a pilot study","volume":"11","author":"Pinker","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2022.09.002_b0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11307-017-1087-5","article-title":"Changes in tumor biology during chemoradiation of cervix cancer assessed by multiparametric MRI and hypoxia PET","volume":"20","author":"Georg","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.radonc.2022.09.002_b0135","doi-asserted-by":"crossref","first-page":"e0141684","DOI":"10.1371\/journal.pone.0141684","article-title":"Simultaneous [18F]FDG-PET\/MRI: correlation of apparent diffusion coefficient (ADC) and standardized uptake value (SUV) in primary and recurrent cervical cancer","volume":"10","author":"Brandmaier","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2022.09.002_b0140","doi-asserted-by":"crossref","first-page":"5063285","DOI":"10.1155\/2018\/5063285","article-title":"Cervical cancer: associations between metabolic parameters and whole lesion histogram analysis derived from simultaneous (18)F-FDG-PET\/MRI","volume":"2018","author":"Meyer","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0145","doi-asserted-by":"crossref","first-page":"28285","DOI":"10.18632\/oncotarget.16043","article-title":"Parameters of simultaneous 18F-FDG-PET\/MRI predict tumor stage and several histopathological features in uterine cervical cancer","volume":"8","author":"Surov","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2022.09.002_b0150","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00259-015-3131-5","article-title":"Integrated PET\/MRI for whole-body staging of patients with primary cervical cancer: preliminary results","volume":"42","author":"Grueneisen","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0155","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-17-3806","article-title":"Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients","volume":"78","author":"Hompland","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0160","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1158\/0008-5472.CAN-20-0950","article-title":"MR imaging distinguishes tumor hypoxia levels of different prognostic and biological significance in cervical cancer","volume":"80","author":"Hillestad","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0165","doi-asserted-by":"crossref","first-page":"102841","DOI":"10.1016\/j.ebiom.2020.102841","article-title":"Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity","volume":"57","author":"Fjeldbo","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2022.09.002_b0170","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2016.08.002","article-title":"A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer","volume":"120","author":"Han","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jmri.1880070113","article-title":"Modeling tracer kinetics in dynamic Gd-DTPA MR imaging","volume":"7","author":"Tofts","year":"1997","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2022.09.002_b0185","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/j.ijrobp.2011.05.050","article-title":"Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance","volume":"82","author":"Andersen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.09.002_b0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/IGC.0000000000001207","article-title":"Prognostic impact of pretreatment fluorodeoxyglucose positron emission tomography\/computed tomography SUVmax in patients with locally advanced cervical cancer","volume":"28","author":"Cima","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.radonc.2022.09.002_b0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-016-0177-8","article-title":"For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET\/CT quantification, regardless of acquisition time","volume":"6","author":"Sher","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/nbm.3377","article-title":"Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer","volume":"28","author":"Barnes","year":"2015","journal-title":"NMR Biomed"},{"key":"10.1016\/j.radonc.2022.09.002_b0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.radonc.2019.02.012","article-title":"Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer","volume":"135","author":"Ho","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0210","article-title":"Pretreatment [(18)F]FDG PET\/CT prognostic factors in patients with squamous cell cervical carcinoma FIGO IIIC1","volume":"11","author":"Burchardt","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.radonc.2022.09.002_b0215","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-20-4450","article-title":"Standardized uptake value for (18)F-fluorodeoxyglucose is a marker of inflammatory state and immune infiltrate in cervical cancer","volume":"27","author":"Floberg","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/JCO.2002.20.3.680","article-title":"Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer","volume":"20","author":"Fyles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0167-8140(99)00175-9","article-title":"Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization","volume":"54","author":"Sundfor","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0230","first-page":"4509","article-title":"Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix","volume":"56","author":"Hockel","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0235","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0240","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1093\/jrr\/rrw007","article-title":"The impact of hypoxia and its modification of the outcome of radiotherapy","volume":"57","author":"Horsman","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2022.09.002_b0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13014-016-0612-z","article-title":"Short-course PET based simultaneous integrated boost for locally advanced cervical cancer","volume":"11","author":"Arnesen","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.002_b0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2020.09.013","article-title":"Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer","volume":"153","author":"van Houdt","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022042669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022042669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:22:12Z","timestamp":1759123332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022042669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"alternative-id":["S0167814022042669"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.09.002","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET\/CT in locally advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}